Pilot, Syndros, Decreasing Use of Opioids in Breast Cancer Subjects With Bone Mets

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

December 19, 2018

Primary Completion Date

October 30, 2020

Study Completion Date

April 26, 2021

Conditions
Bone MetastasesBreast CancerPain
Interventions
DRUG

Syndros

"As noted in arm description. For patients who have side effects secondary to Sydnros, the dose will be decreased as below:~Dose subject is taking Reduction recommendation 8.4mg BID Decreased to 8.4mg AM , 4.2mg PM (or it can be 4.2g in AM and 8.4mg in PM- depending on their side effect timing) 8.4mg AM, 4.2mg PM (or vice versa) 4.2mg BID 4.2mg BID 4.2mg once a day 4.2mg once a day Stop and take off study"

Trial Locations (1)

85742

University of Arizona, Tucson

All Listed Sponsors
lead

University of Arizona

OTHER

NCT03661892 - Pilot, Syndros, Decreasing Use of Opioids in Breast Cancer Subjects With Bone Mets | Biotech Hunter | Biotech Hunter